Varlitinib for cell activation

Varlitinib is a potent inhibitor of the epidermal growth factor receptor (EGFR) family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone. 

N/A

845272-21-1

466.94

Biochemicals

(R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine

C₂₂H₁₉ClN₆O₂S

White solid

N/A

No

Yes

≥98% by HPLC

DMSO

-20°C

gel pack

36 months

Protect from air and light

cell

For cells, cell lines and tissues in culture till half confluency.